World's Best Scientists 2026 revealed!
Michele Baccarani

Michele Baccarani

Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
133
Citations
89694
World Ranking
2182
National Ranking
44

Michele Baccarani publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michele Baccarani sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,402 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michele Baccarani D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michele Baccarani sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 133 D-Index — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Michele Baccarani is affiliated with the University of Bologna in Italy and has an extensive research record in the field of medicine, with a primary focus on hematology. Their work spans multiple subfields, including genetics, rheumatology, public health, environmental and occupational health, and oncology.

Their research largely centers on hematologic malignancies, particularly chronic myeloid leukemia (CML) and related leukemias. The main topics covered in their publications include chronic myeloid leukemia treatments, chronic lymphocytic leukemia research, eosinophilic disorders and syndromes, acute lymphoblastic leukemia research, acute myeloid leukemia research, HER2/EGFR in cancer research, and lymphoma diagnosis and treatment.

Frequent publication venues for Michele Baccarani include journals specializing in hematology and oncology such as Leukemia, Blood, Clinical Lymphoma Myeloma & Leukemia, Frontiers in Oncology, and Blood Advances.

Some recent papers authored or coauthored by Michele Baccarani are:

  • The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia (2020, Leukemia)
  • High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020, Leukemia)
  • INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia (2021, Blood Advances)
  • Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives (2020, Journal of Clinical Medicine)
  • BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS (2020, Leukemia)

Throughout their career, Michele Baccarani has collaborated frequently with a consistent group of coauthors, including Fausto Castagnetti, Gianantonio Rosti, Simona Soverini, Massimiliano Bonifacio, and Francesco Albano.

Best Publications

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

    Hagop Kantarjian;Neil P. Shah;Andreas Hochhaus;Jorge Cortes

  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • Prognostic discrimination in "good-risk" chronic granulocytic leukemia

    JE Sokal;EB Cox;M Baccarani;S Tura

  • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

    Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Andreas Hochhaus;Richard A. Larson;François Guilhot;Jerald P. Radich

  • Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

    Michele Cavo;Paola Tacchetti;Francesca Patriarca;Maria Teresa Petrucci

  • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

    Timothy P Hughes;Michael W Deininger;Andreas Hochhaus;Susan Branford

  • A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

    Joerg Hasford;Markus Pfirrmann;Rüdiger Hehlmann;Norman C. Allan

  • Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

    Jorge E. Cortes;Giuseppe Saglio;Hagop M. Kantarjian;Michele Baccarani

  • Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

    Andreas Hochhaus;Hagop M. Kantarjian;Michele Baccarani;Jeffrey H. Lipton

  • Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

    Hagop M. Kantarjian;Neil P. Shah;Jorge E. Cortes;Michele Baccarani

  • Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients.

    S A Pileri;S Ascani;M C Cox;C Campidelli

  • Chronic myeloid leukaemia

    Rüdiger Hehlmann;Andreas Hochhaus;Michele Baccarani

Frequent Co-Authors

Giovanni Martinelli
Giovanni Martinelli University of Bologna
Giuseppe Saglio
Giuseppe Saglio University of Turin
Michele Cavo
Michele Cavo University of Bologna
Sante Tura
Sante Tura University of Bologna
Jorge E. Cortes
Jorge E. Cortes Augusta University
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Francois Guilhot
Francois Guilhot Grenoble Alpes University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Looking to explore alternate healthcare roles or accelerate your career? There are several flexible online degrees and fast-track programs that can help you get started or advance in the medical field, even if you don’t plan to pursue a traditional MD.

For registered nurses aiming for top leadership roles, a dnp program without clinical hours may offer an expedited route to doctoral-level credentials. Aspiring practical nurses can consider lpn online programs that provide a fast, flexible entry point into healthcare.

Nurses seeking specialized mental health training may benefit from the msn to pmhnp online pathway, enabling advanced practice in psychiatric and mental health nursing. Prefer the administrative side? A bachelors in health administration provides business and management skills for leadership in clinics, hospitals, and health organizations.

Each of these online options allows you to balance education with work and personal commitments, paving multiple career pathways in America's diverse healthcare system.

Best Scientists Citing Michele Baccarani

Trending Scientists

Recently Published Articles